Testosterone’s Overlooked Role in the Treatment of Diabetes in Men

By Edward M. Lichten, MD

For most of my 60 years, I’ve dreamed of finding a medical treatment or cure that could improve humankind. It has been my mission and lifetime quest.

Fifteen years ago, I rediscovered the reparative properties of bioidentical testosterone. It not only reversed my slide into old age, but also reversed my male patients’ diabetes. A hospital-supervised study soon followed, showing that testosterone replacement for men with diabetes was more important than oral diabetic medications, and for some, more important than insulin.

What I could not imagine then was that almost every diabetes specialist, my affiliated national hospital chain, and the state-supervised health insurance carrier would brand me an “enemy of the state” and move to destroy my medical practice and credibility. The American Medical Association provided no support.

This is the story of the inexpensive hormone that can displace up to $20 billion in direct pharmaceutical sales yearly—if only the truth becomes known. > > >
In the First World War, an unsubstantiated report alleged that a dead soldier's testicles were transplanted into the abdominal wall of a man with gangrene. The story goes that the man recovered and did not require amputation. This story might have been considered whimsical, were it not for the work of the Danish physician Jens Moller, MD, between 1950 and 1984. Dr. Moller and approximately 250 other European doctors used injections of bioidentical testosterone to treat diabetes, gangrene, and related heart disease in more than 10,000 male and female patients. Dr. Moller's enthusiasm overshadowed the observation that the high testosterone dosages used increased the incidence of heart disease in the women who were treated. This led to his public humiliation, a disbanding of the European physicians, and a misconception that testosterone is dangerous.

When I turned 45, I "crashed" seemingly overnight, transformed from an enthusiastic, hard-working, physically potent man to a depressed, lethargic, and exhausted old man. My symptoms included night sweats so extreme that I had to take two showers every night. My colleagues had no idea what to do; one offered to admit me to the hospital to seek an answer. As a physician, however, I knew the hospital offered no answers.

I discovered the cause of this malaise from observations made by older patients in my gynecology practice. Two women told me that their 70-year-old husbands had the same symptoms. This compelled me to conduct "menopausal" laboratory tests on my own blood. The fortunate result is that I was one of the first men to be recognized as "andropausal" (experiencing symptoms of "male menopause"). With this newfound information, I asked my urologist about testosterone replacement. He told me that no one believed in testosterone for men, it was too dangerous, and that the laboratory tests were best explained by the many menopausal women I was treating in my practice—in other words, they had influenced my lab test results!

I searched the literature, found a doctor who believed in testosterone replacement, and began testosterone replacement therapy in 1995. My life has never been sweeter since I began "drinking from my own bioidentical fountain of youth."

Pictures on my website testify to the dramatic changes in my physical appearance. At 42, I appear tired and wrinkled. At 52, I look muscular and lean, with a renewed enthusiasm radiating from my body and face. My female patients noticed the difference and were intrigued, as low-dose testosterone replacement therapy was a mainstay of my treatment of menopausal women. Worried about their husbands' erectile dysfunction, lack of libido, and general health, they asked me if I would treat their husbands. I consented, and soon found myself treating "Joe," a five-foot, ten-inch, 295-pound man with adult-onset diabetes.

At the age of 48, Joe confided that he was worried about living long enough to see his daughter grow up. Once physically active, he could barely walk up a flight of stairs without becoming breathless. He knew that being diabetic severely affected his heart, and he could not lose weight, though he had tried.

After performing a glucose tolerance test with insulin levels, I determined that Joe was an early diabetic. I began administering weekly testosterone injections and monitoring Joe's blood sugar levels. During the first week of treatment, Joe's blood glucose dropped into the normal range. He felt better and was able to walk up the stairs without difficulty.

During the first month of treatment, Joe lost 20 pounds without even trying. The second month, he joined a gym and lost another 20 pounds. After the third month, Joe had lost another 10 pounds. After a year of testosterone replacement, Joe weighed 215 pounds—80 pounds less than at the onset of treatment. At 18 months, his repeat glucose tolerance test and insulin and testosterone parameters were normal. Now able to run on a treadmill for 90 minutes, Joe was clinically no longer a diabetic. When his wife received her biweekly testosterone injection, she reported that her husband's bioidentical hormone replacement program with testosterone was more effective than prescription medications like Viagra® in enhancing his sexual function.

In the hospital, "Hugh," a 59-year-old insulin-dependent diabetic, was scheduled to undergo amputation of his finger. He had developed an infection from repeated glucose-testing lancets, which had eaten away the tissue all the way to the bone. In the hospital, Hugh was listless, unshaven, had no appetite, and dis-
played the ominous “Q-sign” (tongue hanging out the side of his mouth). As a family friend, I was beseeched to do something, so I offered an injection of short-acting testosterone. The hospital was in an uproar, as this was considered an unapproved therapy for diabetes.

Hugh's blood sugar dropped 50 points the first day after the injection, and he got out of bed, shaved, and ate his meals. With two more injections that week, his finger started to heal, and the amputation was cancelled. After Hugh returned home, his wife forbade any more testosterone injections. He no longer suffered from erectile dysfunction. Although Hugh died of cardiac disease four years later, he died with his finger healed and intact.

**Clinical Success Leads to Hospital Study**

Armed with this information, I approached my colleague James Sowers, MD, a professor at Wayne State University in Detroit. Dr. Sowers is considered one of America's foremost authorities on diabetes. Dr. Sowers was intrigued by my observations, and we devised a pilot study for diabetic men in 1997. After baseline blood work and testing of their sex hormones (testosterone, estradiol, sex hormone-binding globulin), prostate-specific antigen (PSA), and glucose with insulin, the volunteers would be treated with monthly testosterone implants. They would be seen monthly for three months while on testosterone, and then for four months while off the testosterone injections. Testing occurred at regular one-month intervals.

One limitation of standard medical care is that the physician rarely performs a glucose tolerance test and almost never performs the corresponding insulin measurements. Any deviation from optimal glucose tolerance suggests metabolic syndrome, pre-diabetes, and/or insulin resistance. When blood sugar is high, glucose molecules join hemoglobin, forming glycated or glycosylated hemoglobin in red blood cells, termed hemoglobin A1c (HbA1c). HbA1c levels greater than 6% indicate long-term elevation of blood sugar levels, which has been associated with increased risk of diabetic complications.

In the 1997-1999 pilot study, 35 adult men with diabetes volunteered for treatment. Fifteen men were already on insulin, and 10 were considered “brittle” diabetics, as they used 80-120 units of insulin per day and were prone to precipitous drops in blood sugar called hypoglycemia. Since a hypoglycemic attack can result in coma or death, few doctors aggressively work to lower these patients' blood sugar levels to achieve a preferred 6% HbA1c blood reading.

Our initial evaluation showed that every man who was diabetic was low in testosterone. (Ten years later, Harvard scientist Eric Ding similarly noted that low testosterone was associated with an elevated risk of diabetes.) Our laboratory measurements relied not only on the absolute number of total testosterone (reference range: 251-1000 ng/dL), but also on the measurement of bioavailable (that is, circulating and usable) free testosterone.

Having no preconceived expectation, the study followed the insulin-requiring adult diabetics for three months. Most of the participants reduced their insulin requirements by half, without changing their hemoglobin A1c. Men who previously needed 120 units of insulin now needed 60 units; those who previously used 80 units now needed only 40. However, our next observation may be destined to change the treatment of diabetes forever. We found that the diabetic men on testosterone injections not only had better glycemic control, but also had no dangerous hypoglycemic attacks.

Testosterone therapy also produced impressive results in men with adult-onset diabetes who were managing their condition with therapeutic diet and oral medications but not insulin. This group of 20 men comprised two groups. The two-hour glucose tolerance test with insulin showed that six of the men were “early”...
diabetics, with a pattern of hypersecretion of insulin and low testosterone. With testosterone replacement and a normalization of free testosterone levels, many of these men were able to discontinue their use of oral hypoglycemic agents and improve their HbA1c levels. For those who could not reach an HbA1c level of 6%, therapy was restarted with the most inexpensive generic hypoglycemic agents. These men on testosterone therapy were uniformly pleased with their reawakened vigor, the loss of inches from their waistlines, and improved workout performance. However, for the 14 men with adult-onset diabetes who were taking oral medications, their personal physicians had not realized they were in fact in the "burned out" stage of the condition, meaning that there was very little pancreatic insulin-producing capacity. The insulin part of the glucose tolerance test showed no fourfold increase in insulin value at one or two hours—instead, the numbers were flat and relatively unchanged. Therefore, these men—who represent more than half of adult men on oral agents—were taking expensive medications that were practically worthless for them. Some of the men were able to achieve better blood sugar control using testosterone alone, while some would eventually develop a need for insulin.

**Table 1. Testosterone Improves Blood Sugar, HbA1c in "Anthony," a 50-Year-Old Diabetic**

<table>
<thead>
<tr>
<th>Date</th>
<th>24-hour long-acting insulin use</th>
<th>Glucose (mg/dL)</th>
<th>HbA1c (%)</th>
<th>Testosterone (ng/dL)</th>
<th>Sex Hormone-Binding Globulin (nmol/mL)</th>
<th>Treatment: weekly testosterone injections</th>
</tr>
</thead>
<tbody>
<tr>
<td>7/18/06</td>
<td>14 units</td>
<td>488</td>
<td>&gt;18</td>
<td>643</td>
<td>38</td>
<td>2</td>
</tr>
<tr>
<td>7/29/06</td>
<td>30 units</td>
<td>141</td>
<td>15.7</td>
<td>—</td>
<td>—</td>
<td>2</td>
</tr>
<tr>
<td>8/06/06</td>
<td>40 units</td>
<td>154</td>
<td>15.2</td>
<td>—</td>
<td>—</td>
<td>1.5</td>
</tr>
<tr>
<td>8/12/06</td>
<td>50 units</td>
<td>—</td>
<td>13.5</td>
<td>953</td>
<td>—</td>
<td>1</td>
</tr>
<tr>
<td>8/28/06</td>
<td>60 units</td>
<td>161</td>
<td>11.8</td>
<td>493</td>
<td>—</td>
<td>1</td>
</tr>
<tr>
<td>9/02/06</td>
<td>70 units</td>
<td>165</td>
<td>11.2</td>
<td>522</td>
<td>—</td>
<td>1</td>
</tr>
<tr>
<td>9/15/06</td>
<td>75 units</td>
<td>—</td>
<td>10.1</td>
<td>—</td>
<td>—</td>
<td>1</td>
</tr>
<tr>
<td>9/22/06</td>
<td>80 units</td>
<td>308</td>
<td>9.5</td>
<td>894</td>
<td>—</td>
<td>1</td>
</tr>
<tr>
<td>10/28/06</td>
<td>75 units</td>
<td>47</td>
<td>8.3</td>
<td>—</td>
<td>—</td>
<td>1</td>
</tr>
<tr>
<td>11/14/06</td>
<td>75 units</td>
<td>135</td>
<td>7.9</td>
<td>297</td>
<td>—</td>
<td>1.5</td>
</tr>
<tr>
<td>12/18/06</td>
<td>88 units</td>
<td>175</td>
<td>7.7</td>
<td>—</td>
<td>—</td>
<td>1.5</td>
</tr>
<tr>
<td>1/27/07</td>
<td>100 units</td>
<td>65</td>
<td>7.4</td>
<td>792</td>
<td>—</td>
<td>1.5</td>
</tr>
</tbody>
</table>

When "Charles," an insulin-requiring diabetic on 100 units per day, came for a follow-up visit, I was surprised to see his finger-stick glucose at the low value of 37 mg/dL. When questioned, he told me that his internist had called him the night before, alarmed at the low glucose reading from a blood sample sent to a national laboratory. Charles had no symptoms, though he knew the symptoms of hypoglycemia and impending coma. I instructed him to reduce his insulin by another 10 units per day, and he agreed to do so. But why didn't his blood sugar levels crash?

According to the medical literature, including a report by Tiblin, testosterone sensitizes men's cells to more readily admit glucose. In other words, it decreases insulin resistance in men. Therefore, whatever insulin is available in men works much more efficiently in the presence of testosterone. Of note, the female hormone estradiol works counterproductively for men, worsening insulin resistance. When questioned, he told me that his internist had called him the night before, alarmed at the low glucose reading from a blood sample sent to a national laboratory. Charles had no symptoms, though he knew the symptoms of hypoglycemia and impending coma. I instructed him to reduce his insulin by another 10 units per day, and he agreed to do so. But why didn't his blood sugar levels crash?

Another interesting patient of mine was "Anthony," a 50-year-old African-American male without insurance, employment, or regular meals, let alone medication. As shown in Table 1 above, his fasting glucose was 488 mg/dL and his HbA1c was greater than 18%. I immediately treated Anthony with
twice the standard dose of testosterone and tracked his blood sugar daily. Over the next four months, I titrated Anthony's long-acting insulin from 20 units to 90 units per day, and continued a sliding scale of regular insulin at approximately 20 units per day with meals.

What I never expected was how quickly Anthony's intracellular glycogen stores would normalize. In four weeks, his HbA1c dropped from 18 to 15.7%; at three months, it was 11%; and at five months, it was 7.4%.

The Journal of the American Medical Association reported that in the best of circumstances, only 40% of insulin-dependent men could achieve an HbA1c level of 8% or lower. Yet I had driven the worst diabetic from a level of 18% to 7.4%. Best of all, the full potential of Anthony's treatment had not even been realized, since it had been only five months.

Anthony suffered memory lapses originating from the high glucose in his bloodstream and brain tissue. This is not unusual for uncontrolled diabetics. One evening, he injected 30 units of regular, short-acting insulin instead of his usual long-acting insulin. He called me and I advised him to eat his dinner and check his glucose levels every two hours. Anthony's glucose testing never showed a value below 129 mg/dL. Another time, he awoke at 4 a.m., took his regular insulin, and went back to bed without eating. His morning glucose was in the range of 80-90 mg/dL. Remarkably, he suffered no blood sugar "crash," coma, or severe symptoms.

As shown in Table 1, no matter how much testosterone was given to Anthony, his total testosterone never exceeded the upper limits of normal for men (1000-1200 ng/dL). He never developed polycythemia, a high red blood cell count that is the most common complication of continuous testosterone injections. (Its solution is simple: donate blood to the Red Cross once every four months.)

I have the same goal as all doctors who treat diabetes: an HbA1c of 6.0%. In my office, with time and cooperation from my patients, almost all men are stabilized with an HbA1c of 6-7%. Glucose levels below 110 mg/dL are common in my patients with diabetes.

Just last year, Dr. Dheeraj Kapoor published a study of 20 diabetic men reporting improvement in glycated hemoglobin (HbA1c), fasting blood glucose, insulin sensitivity, waist circumference, and blood lipid levels. Testosterone is an important and beneficial treatment for diabetic men—perhaps even more so than insulin. While insulin is applicable to 10% of men with type II diabetes, testosterone could be useful to almost 100%. Simple, effective, inexpensive, and safe, testosterone is truly man's best adjunct for a long and healthy life—whether or not he has diabetes.

**The Diabetes Explosion**

Diabetes is fast becoming a global pandemic of nearly unimaginable proportions. Its incidence is approaching 25% of the general population over 60. With the development of adult-onset or nutritional diabetes in teenagers and adolescents, and its predilection for dark-skinned individuals, it is estimated that one in three children born in the United States today will become diabetic.

Clearly, it is time to embrace new therapeutic approaches to averting this crippling disease. Testosterone therapy may be one of the most promising new approaches for men seeking to prevent and manage diabetes and other conditions associated with poor blood sugar control.

**Risks of Testosterone Therapy**

For insulin-requiring diabetic men without contraindications, doctors can administer testosterone injections and follow patients' improved glycemic control, reducing their insulin requirements accordingly. Not only will the improved glycemic control reduce morbidity (disease incidence), but testosterone replacement may produce beneficial effects for the heart, bones, memory, mood, sexual performance, and red blood cell production, which could reduce the risk of numerous conditions—not only heart attack, Alzheimer's disease, and osteoporosis, but also dialysis-associated anemia.

In documented cases, men receiving kidney dialysis required less anemia medication when they were receiving treatment with an anabolic steroid. If hospitals incorporated testosterone protocols for men undergoing dialysis, more than one third of costs related to anemia medications such as Epogen® might be eliminated.

The risk of infection, bleeding, and potential allergic reaction to the sesame oil used as a carrying agent in the testosterone injection is small. The risks, expounded in the litera-
tumor, are those related to prostate and testicular cancer. It is a contraindication to use testosterone in the presence of prostate cancer. Yet I have had only one male patient in the last 10 years who developed prostate cancer while on testosterone therapy. In fact, that patient was instructed to go back on testosterone by his doctor at the Mayo Clinic after only two years of observation post-surgery.

A study by Dr. Abraham Morgentaler found that testosterone may be protective against prostate cancer. In a large study of men with low testosterone and normal prostate-specific antigen (4 ng/mL or lower), up to one in three had biopsy-proven prostate cancer. Morgentaler found that testosterone may be protective against prostate cancer. In a large study of men with low testosterone and normal prostate-specific antigen (4 ng/mL or lower), up to one in three had biopsy-proven prostate cancer. Men with total testosterone levels of 250 ng/dL or less had almost twice the incidence of prostate cancer compared to men whose levels were above 250 ng/dL. It is possible that inadequate testosterone levels in men are associated with a higher risk of prostate cancer!

From a medical and health perspective, doctors should have the appropriate laboratory tests performed on all male patients over 35 years of age, especially those with suspected health issues. Without the HbA1c, a physician would not suspect that so many men have long-term elevations in blood sugar. For those who prefer to be tested before seeing a physician, blood tests can be ordered through the Life Extension Foundation.

### THE DIABETES CONSPIRACY

In 1999, Blue Cross visited my medical office for what I was told was a routine audit. Although I was seeing 150 patients a week, 50 weeks a year, the “routine” Blue Cross audit involved almost 3,000 records. While the reviewer complimented me on my 97% documentation rate, Blue Cross responded by requesting that I repay them $138,000 and submit to a continuing or “rolling” audit. That was after they sent investigators to the homes of many patients who had had procedures done in the office, looking for even one case of a procedure “billed but not done.” They even told my patients that I was under investigation for “fraud” (though years later a Blue Cross attorney admitted that it was, in fact, a fraudulent audit).

While this matter was pending discussion by the attorneys, in January 2004 Blue Cross placed me in the Pre-Payment Utilization Review (PPUR) program. This is the “dead-letter” box: no matter how extensive the typed medical record notes, or how many laboratory results sheets were attached or operative notes included, there was little or no payment from Blue Cross. Since Blue Cross was the insurance of more than 85% of my patients, within six months I lost my savings, my practice, and more than $300,000 in income.

When I resumed my practice in Michigan in May 2005, I no longer participated with Blue Cross, instead collecting my professional fees directly from my patients. However, in September 2005, the PPUR program head notified me that I was still in PPUR. Then the PPUR division did the unthinkable, in violation of Michigan law and the state organizational charter for Blue Cross: they refused to reimburse my patients for nearly every professional service rendered in my office. One letter to a patient from the PPUR program leader went so far as to suggest that the patient get another doctor. To others, they stated, “I am so sorry that Dr. Lichten is your doctor.”

Although I had met with the PPUR personnel and physicians in April 2004 and again in September 2006, they ignored the matter. All of these abusive and destructive actions had occurred after Blue Cross had learned of my scientific rediscovery and breakthrough treating diabetic men with inexpensive testosterone injections. No doctor, administrator, or anyone from their legal team would face the obvious—why attack a doctor who could save Michigan $50 million in medication expenses in the first year? Couldn’t there be a potentially tenfold savings in medical expenses related to hospitalizations, amputations, heart attacks, and blindness treatments? Even a Blue Cross executive admitted that this action by the PPUR division was highly unusual. But no one at Blue Cross would stop this abuse that had been going on for seven years, starting with that first unannounced audit.

As the investigators will attest, every major carrier—except Blue Cross Blue Shield of Michigan—pays for my services. I am a medical doctor with 35 years of experience as a physician, researcher, and educator. I continue to write, lecture, and educate my colleagues. I have published more than 33 peer-reviewed publications, given 80 local, national, and international lecture presentations, and am considered one of the foremost innovators in the treatment of menstrual pain, migraine, menopause, and now diabetes.

### Conclusion

Thousands of years ago, it was recognized that castration took away a male’s manhood, both physically and emotionally. Today, hormones in our food supply (such as bovine growth hormone) and environmental xenoestrogens (synthetic substances that imitate the effects of estrogens, such as bisphenols and phthalates) may contribute to the dramatic decline in bioavailable testosterone and sperm count that has been observed in American men over the past 50 years. This same period has coincided with a meteoric rise in the incidence of diabetes and heart disease in the US.
THE "FOUND THE CURE" FOUNDATION

To publicize the fact that there are natural, inexpensive cures for many diseases, I created the "Found the Cure" Foundation. As part of this effort, I continue to travel to medical and hospital groups in the United States and worldwide to demonstrate one- and three-month testosterone-injection protocols for treating male menopause, diabetes, and heart disease, and female menopause, low libido, and osteoporosis. More information about these simple, safe, and inexpensive biological methods for disease management can be obtained by downloading my book The Diabetes Conspiracy, which outlines treatments that make standard prescription medications for insomnia, PMS, migraine, menopause, osteoporosis, and cholesterol reduction obsolete.

For more information, please visit www.foundthecure.com.

Optimizing testosterone levels may provide men with powerful protection against the risk of pre-mature death and diseases such as diabetes, heart disease, osteoporosis, Alzheimer's, and even prostate cancer.

Edward M. Lichten, MD, FACS, is a Fellow of the American College of Surgeons and a Fellow of the American College of Obstetricians and Gynecologists. Dr. Lichten can be contacted through www.usdoctor.com or by calling 866-532-4254 or 248-593-9999.

References


PHARMACEUTICAL PRODUCTS MENTIONED IN THIS ARTICLE

- Testosterone pellets contain bioidentical crystalline testosterone compressed in a matrix that allows for stable release over 4-6 weeks.
- Testosterone injections provide chemically modified testosterone with a molecule that delays absorption for 2-3 days. This molecule is typically enanthate, propionate, or cypionate. Injections result in rapid peak and dissipation within 4-6 days.
Copyright of Life Extension is the property of Life Extension Foundation and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.